Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)

Exclusion Criteria

• •Clinically significant abnormalities other than a history of chronic HBV infection;
• •Concomitant clinically significant other liver diseases;
• •Previous/current manifestations of hepatic decompensation;
• •Significant hepatic fibrosis or cirrhosis;
• •Presence of protocol-specified laboratory abnormalities;
• •History of malignancy or ongoing assessment of possible malignancy;
• •Those allergic to AHB-137 or its components;
• •Participants with recent major trauma or major surgery, or planning surgery;
• •Those who are participating in another clinical trial, or have not undergone a protocol-specified washout period prior to this study;
• •Prior/current use of prohibited medications;
• •Inappropriate for participation in this trial as judged by the investigator.